Strong growth for its orphan, rheumatology, and primary care drugs translated to a great first quarter for Horizon.
News & Analysis: Horizon Pharma
Horizon's experimental thyroid eye disease treatment hit the mark in a late-stage trial today.
Horizon's shares got a boost from the company's outstanding third-quarter earnings report yesterday.
The specialty pharma company announced record results for the second quarter of 2018.
The biopharma successfully staved off a generic challenger for its most important drug.
Horizon Pharma may be getting back on track after a strong second quarter.
Horizon's revised outlook for 2017 sent investors heading for the exits on Monday.
Investors received some good news heading into 2017 a week after the biopharma pulled the plug on a late-stage clinical trial.
Horizon's all-important late-stage trial for a rare nerve disorder goes belly up.
Political controversy aside, the drugmaker's shares are a compelling buy now after sinking in October. Here's why.
A solid third-quarter earnings report has the drugmaker's shares heading higher.